Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$666.2M
40M shares
52-week range
$6.27 – $17.40
92% from low
Exchange
NASDAQ
ADRC
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
www.brainsway.comNo one on the platform currently holds BWAY.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 518,420 | $6.9M |
| Execution date | Ratio |
|---|---|
| 2026-03-04 | 2-for-1 |
No one on the platform has traded BWAY yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $68M | +30.9% | $0.31 | $0.22–$0.39 | 53.7× | 2 |
| 2027 | $83M | +22.2% | $0.48 | $0.35–$0.62 | 34.1× | 2 |
| 2028 | $99M | +19.9% | $0.53 | $0.50–$0.55 | 31.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $0.10 | $0.07 | -30.0% |
| 2026-05-13 | $0.05 | $0.12 | +140.0% |
| 2026-03-11 | $0.06 | $0.14 | +133.3% |
| 2025-11-11 | $0.11 | $0.08 | -27.3% |
| 2025-08-13 | $0.04 | $0.05 | +25.0% |
| 2025-05-13 | $0.02 | $0.04 | +100.0% |
| 2025-03-11 | $0.05 | $0.08 | +60.0% |
| 2024-11-12 | $0.01 | $0.04 | +207.7% |
| $409M |
| — |
| NPCENeuroPace, Inc. | $14.70 | +0.96% | $501M | — |
| RXSTRxSight, Inc. | $6.93 | -1.84% | $287M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Yesterday's double-digit moves came from the full range of sentiment scores. $NBIS $WYFI $EAT $BWAY $JMIA up while LQDA fell.
View on StockTwits ↗$BWAY reported 0.07 EPS and 17.11 revenue for Q2. http://www.estimize.com/intro/bway?chart=historical&metric_name=eps&utm_content=BWAY&utm_
View on StockTwits ↗$BWAY Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.07 up 40.00% YoY • Reported revenue of $17.11M up 35.43% YoY • BrainsWay now expects full-year 2026 revenue of $68 million to $70 million, operating income between 13.5% and 14% of revenue, and Adjusted EBITDA of $13 million to $14 million for the period.
View on StockTwits ↗$STIM clinic biz on fire, even before psychedelics roll out and $CMPS partnership financial impact. But device biz also inflecting, with 10% underlying growth and the largest installed base in the US. Seems like a good time to remember $STIM trades at less than 1.5x revenue while peer $BWAY trades at 9x, despite smaller US installed base.
View on StockTwits ↗Can $BWAY continue to $ASND thru da $$$$ wen they all report eps ONTO 🐒🍌🧠⏰♾️
View on StockTwits ↗BTIG initiated coverage on two companies with “buy” ratings that it believes are undervalued players in the transcranial magnetic stimulation (TMS) space. Analyst Sam Eiber assigns target prices of $5 to Neuronetics $STIM and $18 to BrainsWay $BWAY https://biotuesdays.com/2026/07/20/btig-starts-coverage-of-two-tms-companies-at-buy-sees-anticipated-psilocybin-therapy-approval-as-potential-catalyst-for-both/
View on StockTwits ↗#BrainsWay (NASDAQ: $BWAY ) is continuing its “clinic‑partner” expansion strategy with a new $500K minority‑stake investment in Sound Minds Behavioral, an outpatient behavioral health provider, using preferred equity with milestone options to widen access to Deep TMS across another frontline mental‑health network. #MentalHealth #BehavioralHealth #Depression #DeepTMS https://prismmarketview.com/companies/brainsway-ltd/#news
View on StockTwits ↗Wall St is expecting 0.08 EPS for $BWAY Q2 [Reporting 08/12 BMO] http://www.estimize.com/intro/bway?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$BWAY presented positive real-world data from a 462-patient study showing its Deep TMS technology achieved an 83.5% response rate in patients with comorbid PTSD and major depressive disorder. https://prismmarketview.com/companies/brainsway-ltd/#news
View on StockTwits ↗$DRTS https://thefinanceherald.com/a-brain-cancer-win-got-the-headlines-this-small-cap-has-four-more-cancers-in-the-clinic-nasdaq-drts/ $ORMP $BWAY
View on StockTwits ↗@BrainsWay ($BWAY) reports that favorable insurance coverage for its accelerated Deep TMS protocols has climbed to over 57 million covered lives, expanding access to its noninvasive neuromodulation treatment and strengthening the commercial case for this emerging mental health tech name. https://prismmarketview.com/companies/brainsway-ltd/#news
View on StockTwits ↗$BWAY announced that reimbursement coverage for its SWIFT accelerated Deep TMS protocol has expanded, reaching a cumulative opportunity of more than $57 million. Separately, BrainsWay recently reported that more than 80% of patients treated with the SWIFT protocol remained in remission at 12 months. If confirmed in a peer-reviewed publication with transparent reporting of patient follow-up and missing data, this would represent an exceptional outcome—well above the established benchmarks for any currently available depression treatment modality. This is amazing!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.